HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.047167v1 49/2/260    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van de Wiele, C. Articles by Dierckx, R. A. Search for Related Content PubMed PubMed Citation Articles by Van de Wiele, C. Articles by Dierckx, R. A.

Gastrin-Releasing Peptide Receptor Imaging in Human Breast Carcinoma Versus Immunohistochemistry

¹ Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium; ² Department of Nuclear Medicine and Molecular Imaging, University Medical Centre, Groningen, The Netherlands; ³ Department of Anatomopathology, Ghent University Hospital, Ghent, Belgium; ⁴ Division of Gynaecological Oncology, Ghent University Hospital, Ghent, Belgium; and ⁵ Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium

Correspondence: For correspondence or reprints contact: Christophe Van de Wiele, MD, PhD, Department of Nuclear Medicine, Ghent University Hospital, De Pintelaan 185, 9000B Ghent, Belgium. E-mail: christophe.vandewiele{at}ugent.be

This study reports on the uptake of ^99mTc-RP527 by human breast carcinoma and its relationship to gastrin-releasing peptide receptor (GRP-R) expression as measured by immunohistochemistry (IHC). Methods: Nine patients referred because of a clinical diagnosis suggestive of breast carcinoma and 5 patients with tamoxifen-resistant bone-mestastasized breast carcinoma underwent ^99mTc-RP527 scintigraphy. The findings were compared with routine staging examinations in all patients and with routine histology and IHC GRP-R staining in the first 9 patients. All 9 patients with suspected breast lesions were tumor positive. Results: The uptake of ^99mTc-RP527 was evident in the primary tumor in 8 of 9 patients and in involved lymph nodes and part of the distant metastasis limited to the bone when present. ^99mTc-RP527 uptake was not found in any of the tamoxifen-resistant patients. Conclusion: Uptake by primary breast carcinoma was significantly correlated with the presence of GRP-Rs as assessed by means of IHC.

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				R. Mansi, X. Wang, F. Forrer, S. Kneifel, M.-L. Tamma, B. Waser, R. Cescato, J. C. Reubi, and H. R. Maecke Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides Clin. Cancer Res., August 15, 2009; 15(16): 5240 - 5249. [Abstract] [Full Text] [PDF]

				J. C. Reubi and H. R. Maecke Peptide-Based Probes for Cancer Imaging J. Nucl. Med., November 1, 2008; 49(11): 1735 - 1738. [Abstract] [Full Text] [PDF]